|
Oportuzumab monatox (proposed INN), trade name "Vicinium" is an antineoplastic. Chemically, oportuzumab it is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). The drug is produced by Viventia Bio Vicinium has been evaluated in phase I and II clinical trials in patients with non-muscle invasive bladder cancer.〔Phase I/II study of vicinium given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: Phase I results D. Fitsialos, S. Seitz, E. Wiecek, M. Rasamoelisolo, J. Entwistle, M. Jewett, G. C. MacDonald and N. Glover. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition).〕 In these studies, treatment was associated with clinical benefit. ==References== 〔 Vol 24, No 18S (June 20 Supplement), 2006: 4580 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Oportuzumab monatox」の詳細全文を読む スポンサード リンク
|